Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The future of type 1 cannabinoid receptor allosteric ligands
Mariam Alaverdashvili, Robert B. Laprairie
Drug Metabolism Reviews (2018) Vol. 50, Iss. 1, pp. 14-25
Closed Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

The therapeutic potential of second and third generation CB1R antagonists
Reşat Çınar, Malliga R. Iyer, George Kunos
Pharmacology & Therapeutics (2020) Vol. 208, pp. 107477-107477
Open Access | Times Cited: 109
The Trifluoromethyl Group as a Bioisosteric Replacement of the Aliphatic Nitro Group in CB1 Receptor Positive Allosteric Modulators
Chih‐Chung Tseng, Gemma L. Baillie, Giulia Donvito, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 10, pp. 5049-5062
Open Access | Times Cited: 64
Positive Allosteric Modulation of CB1 Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward
Richard A. Slivicki, Vishakh Iyer, Sonali S. Mali, et al.
Frontiers in Molecular Neuroscience (2020) Vol. 13
Open Access | Times Cited: 57
Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators
Sumanta Garai, Pushkar M. Kulkarni, Peter C. Schaffer, et al.
Journal of Medicinal Chemistry (2019) Vol. 63, Iss. 2, pp. 542-568
Open Access | Times Cited: 53
Emerging strategies targeting CB2 cannabinoid receptor: Biased agonism and allosterism
Paula Morales, Pilar Goya, Nadine Jagerovic
Biochemical Pharmacology (2018) Vol. 157, pp. 8-17
Closed Access | Times Cited: 47
Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation
Dinesh Thapa, Elizabeth A. Cairns, Anna-Maria Szczesniak, et al.
Molecules (2020) Vol. 25, Iss. 2, pp. 417-417
Open Access | Times Cited: 40
Endocannabinoids in Body Weight Control
Henrike Horn, Béatrice Böhme, L. Dietrich, et al.
Pharmaceuticals (2018) Vol. 11, Iss. 2, pp. 55-55
Open Access | Times Cited: 43
Allosteric Modulation of the CB1 Cannabinoid Receptor by Cannabidiol—A Molecular Modeling Study of the N-Terminal Domain and the Allosteric-Orthosteric Coupling
Jakub Jakowiecki, Renata Abel, Urszula Orzeł, et al.
Molecules (2021) Vol. 26, Iss. 9, pp. 2456-2456
Open Access | Times Cited: 30
Allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain
Chunhao Zhu, Xiaobing Lan, Zhiqiang Wei, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 1, pp. 67-86
Open Access | Times Cited: 11
Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist
Pankaj Pandey, Kuldeep K. Roy, Robert J. Doerksen
Journal of Biomolecular Structure and Dynamics (2019) Vol. 38, Iss. 1, pp. 32-47
Open Access | Times Cited: 31
Allosteric Modulators Targeting Cannabinoid cb1 and cb2 Receptors: Implications for Drug Discovery
Francesca Gado, Serena Meini, Simone Bertini, et al.
Future Medicinal Chemistry (2019) Vol. 11, Iss. 15, pp. 2019-2037
Open Access | Times Cited: 30
Allosteric Modulation of Cannabinoid Receptor 1—Current Challenges and Future Opportunities
Szymon Hryhorowicz, Marta Kaczmarek-Ryś, Angelika Andrzejewska-Romanowska, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 23, pp. 5874-5874
Open Access | Times Cited: 30
Novel approaches and current challenges with targeting the endocannabinoid system
Paula Morales, Nadine Jagerovic
Expert Opinion on Drug Discovery (2020) Vol. 15, Iss. 8, pp. 917-930
Open Access | Times Cited: 30
Recent Advances in Endocannabinoid System Targeting for Improved Specificity: Strategic Approaches to Targeted Drug Delivery
Mendhi Henna Dasram, Roderick B. Walker, Sandile M. Khamanga
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13223-13223
Open Access | Times Cited: 16
Natural allosteric modulators and their biological targets: molecular signatures and mechanisms
Marjorie Bruder, Gina Polo, Daniela B. B. Trivella
Natural Product Reports (2020) Vol. 37, Iss. 4, pp. 488-514
Closed Access | Times Cited: 24
Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats
Udita Datta, Leslie K. Kelley, Jason W. Middleton, et al.
Psychopharmacology (2020) Vol. 237, Iss. 12, pp. 3729-3739
Open Access | Times Cited: 19
Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases
Quinn Coughlin, Allen T. Hopper, María‐Jesús Blanco, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 13, pp. 5979-6002
Closed Access | Times Cited: 15
Variously substituted 2-oxopyridine derivatives: Extending the structure-activity relationships for allosteric modulation of the cannabinoid CB2 receptor
Francesca Gado, Kawthar A. Mohamed, Serena Meini, et al.
European Journal of Medicinal Chemistry (2020) Vol. 211, pp. 113116-113116
Closed Access | Times Cited: 14
Potential for endocannabinoid system modulation in ocular pain and inflammation: filling the gaps in current pharmacological options
J. Daniel Lafreniere, Michael E. Kelly
Neuronal Signaling (2018) Vol. 2, Iss. 4
Open Access | Times Cited: 13
The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg
Dan L. McElroy, Andrew J. Roebuck, Quentin Greba, et al.
IBRO Neuroscience Reports (2022) Vol. 12, pp. 121-130
Open Access | Times Cited: 7
A novel allosteric modulator of the cannabinoid CB1 receptor ameliorates hyperdopaminergia endophenotypes in rodent models
Catharine A. Mielnik, Kim S. Sugamori, David B. Finlay, et al.
Neuropsychopharmacology (2020) Vol. 46, Iss. 2, pp. 413-422
Open Access | Times Cited: 10
Psychiatric Disorders and Cannabinoid Receptors
Neal Joshi, Emmanuel S. Onaivi
Advances in experimental medicine and biology (2020), pp. 131-153
Closed Access | Times Cited: 10
Effects of the cannabinoid receptor 1 positive allosteric modulator GAT211 and acute MK-801 on visual attention and impulsivity in rats assessed using the five-choice serial reaction time task
Timothy J. Onofrychuk, Shuang Cai, Dan L. McElroy, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 109, pp. 110235-110235
Closed Access | Times Cited: 10
Negative allosteric modulators of cannabinoid receptor 1: Ternary complexes including CB1, orthosteric CP55940 and allosteric ORG27569
AyoOluwa O. Aderibigbe, Pankaj Pandey, Robert J. Doerksen
Journal of Biomolecular Structure and Dynamics (2021) Vol. 40, Iss. 13, pp. 5729-5747
Open Access | Times Cited: 6
Pharmacological evaluation of enantiomerically separated positive allosteric modulators of cannabinoid 1 receptor, GAT591 and GAT593
Asher L. Brandt, Sumanta Garai, Ayat Zagzoog, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top